Structured evidence table for Reishi Immune Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Reishi Immune Randomized Trial | Recognized as pathogen-associated molecular patterns (PAMPs) in the intestine, β-glucans and proteoglycans boost innate immunity and enhance the adaptive immune response to different antigens. | 3 | Kirdeeva Yulia (2026) | The Inclusion of Dietary and Medicinal Mushrooms into Translational Oncology: Pros and Cons at the Molecular Level |
| Reishi Immune Randomized Trial | Finally, we will discuss the safety, limitations, and clinical experience associated with the use of medical mushrooms in oncology. | 3 | Kirdeeva Yulia (2026) | The Inclusion of Dietary and Medicinal Mushrooms into Translational Oncology: Pros and Cons at the Molecular Level |
| Reishi Immune Randomized Trial | Agaricus bisporus Lentinula edodes Pleurotus ostreatus Pleurotus eryngii Auricularia heimuer Volvariella volvacea Flammulina filiformis Figure 1 First, consumption has increased due to the commercial cultivation of mushrooms. | 3 | Kirdeeva Yulia (2026) | The Inclusion of Dietary and Medicinal Mushrooms into Translational Oncology: Pros and Cons at the Molecular Level |
| Reishi Immune Randomized Trial | 1 2 3 4 5 6 7 8 Agaricus bisporus Pleurotus ostreatus Volvariella volvacea Natural compounds from plants and mushrooms are a source of continuous development for anticancer therapeutics [,,,,]. | 3 | Kirdeeva Yulia (2026) | The Inclusion of Dietary and Medicinal Mushrooms into Translational Oncology: Pros and Cons at the Molecular Level |
| Reishi Immune Randomized Trial | Purpose of review Biochemical recurrence of epithelial ovarian cancer (EOC), defined as rising CA-125 levels without clinical or radiologic evidence of disease, is a frequent and challenging scenario. | 4 | Berman T (2026) | Integrative Oncology for Biochemical Recurrence of Epithelial Ovarian Cancer. |
| Reishi Immune Randomized Trial | Although ovarian cancer-specific trials are limited, IO approaches are safe, feasible, and evidence-informed. | 4 | Berman T (2026) | Integrative Oncology for Biochemical Recurrence of Epithelial Ovarian Cancer. |
| Reishi Immune Randomized Trial | Cytotoxic therapy initiated at this stage does not improve survival and may diminish quality of life. | 4 | Berman T (2026) | Integrative Oncology for Biochemical Recurrence of Epithelial Ovarian Cancer. |
Source documents